Blueprint Medicines Corporation

Blueprint Medicines Corporation is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Blueprint Medicines Corporation is not a good growth stock. Blueprint Medicines Corporation is not very popular among insiders. Blueprint Medicines Corporation is a mediocre stock to choose.
Log in to see more information.
Blueprint Medicines Corp. is a precision therapy company, which focuses on medicines to improve the...

News

Arizona State Retirement System Increases Position in Blueprint Medicines Co. (NASDAQ:BPMC)
Arizona State Retirement System Increases Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Zolmax Arizona State Retirement System lifted its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 2.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities...\n more…

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Acquired by Arizona State Retirement System
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Acquired by Arizona State Retirement System

Ticker Report Arizona State Retirement System increased its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 2.6% in the second quarter, according to its most recent 13F filing with the...\n more…

Rhumbline Advisers Boosts Position in Blueprint Medicines Co. (NASDAQ:BPMC)
Rhumbline Advisers Boosts Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Ticker Report Rhumbline Advisers boosted its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 6.0% in the second quarter, according to its most recent 13F filing with the Securities and...\n more…

Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Victory Capital Management Inc.
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Victory Capital Management Inc.

Ticker Report Victory Capital Management Inc. raised its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 28.5% in the second quarter, HoldingsChannel reports. The firm owned 264,995...\n more…

Blueprint Medicines to Present at Upcoming Investor Conferences
Blueprint Medicines to Present at Upcoming Investor Conferences

PR Newswire Blueprint Medicines to Present at Upcoming Investor Conferences Blueprint Medicines to Present at Upcoming Investor Conferences PR Newswire CAMBRIDGE, Mass., Sept. 10, 2024 CAMBRIDGE, Mass., Sept...\n more…

Candriam S.C.A. Purchases 12,001 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)
Candriam S.C.A. Purchases 12,001 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Ticker Report Candriam S.C.A. increased its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 30.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange...\n more…